COMMUNIQUÉS West-GlobeNewswire

-
Yerbae Expands Colorado Distribution Through Eagle Rock Distributing and King Soopers, Seeking to Mirror Safety Shot’s Success in Major Supermarket Chains
04/02/2025 - 16:46 -
NeuroOne® Regains Compliance with Nasdaq Listing Requirements
04/02/2025 - 16:56 -
Soda Health Achieves HITRUST e1 Certification Demonstrating Foundational Cybersecurity
04/02/2025 - 17:00 -
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
04/02/2025 - 17:45 -
Informations relatives au nombre total de droits de vote et d’actions composant le capital
04/02/2025 - 18:00 -
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
04/02/2025 - 18:24 -
Jushi Announces Support of Adult-Use Cannabis in Pennsylvania Governor’s Annual Budget Proposal and Address
04/02/2025 - 19:00 -
LiveCare Inc. Announces Resolution of Investigation with the U.S. Department of Justice After Proactive Self-Disclosure
04/02/2025 - 20:30 -
Revium Rx (RVRC) Completes Acquisition of LipoVation Ltd.
04/02/2025 - 20:31 -
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025 - 22:00 -
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/02/2025 - 22:01 -
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025 - 22:01 -
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
04/02/2025 - 22:05 -
Exagen Inc. to Participate in Upcoming Investor Conferences
04/02/2025 - 22:05 -
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025 - 22:05 -
InnovAge Announces Financial Results For the Fiscal Second Quarter Ended December 31, 2024
04/02/2025 - 22:05 -
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025 - 22:05 -
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
04/02/2025 - 22:05 -
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2025 - 22:30
Pages